Liproxstatin-1 HCl: Potent Ferroptosis Inhibitor for Acute Renal Failure and Lipid Peroxidation Studies

Executive Summary: Liproxstatin-1 HCl is a nanomolar-potency ferroptosis inhibitor for dissecting iron-dependent regulated cell death in cellular and animal models (APExBIO). It shows an IC₅₀ of 22 nM in cell-based ferroptosis assays and protects against lipid peroxidation and cell death induced by RSL3, L-buthionine sulphoximine, and erastin. The compound yields significant in vivo protection in acute renal failure and hepatic ischemia/reperfusion injury models (Wen et al. 2023). Liproxstatin-1 HCl is selective, with no effect on apoptosis or oxidative stress-induced death. It is supplied as a solid, water- and DMSO-soluble hydrochloride salt and is intended for research only.

Biological Rationale

Ferroptosis is a regulated, iron-dependent form of non-apoptotic cell death characterized by lipid peroxidation. It is mechanistically distinct from apoptosis and necrosis. Ferroptosis is implicated in acute organ injuries, especially acute renal failure and hepatic ischemia/reperfusion injury (Wen et al. 2023). The enzyme GPX4 (glutathione peroxidase 4) is essential in preventing ferroptosis by detoxifying lipid hydroperoxides. Inhibition or depletion of GPX4 leads to uncontrolled lipid peroxidation and ferroptotic cell death. Small-molecule inhibitors like Liproxstatin-1 HCl are vital for delineating the pathways of ferroptosis and for therapeutic research targeting iron-dependent regulated cell death.

Mechanism of Action of Liproxstatin-1 HCl

Liproxstatin-1 HCl (N-(3-chlorobenzyl)-4'H-spiro[piperidine-4,3'-quinoxalin]-2'-amine hydrochloride) acts as a potent, selective inhibitor of ferroptosis. The compound suppresses lipid peroxidation by directly or indirectly preserving GPX4 activity in cells. Liproxstatin-1 HCl prevents ferroptotic cell death induced by RSL3, erastin, and L-buthionine sulphoximine in cell models, including GPX4-deficient and RAS-transformed lines. It does not prevent cell death from apoptotic inducers such as staurosporine or from hydrogen peroxide-driven oxidative stress (APExBIO), underscoring its mechanistic specificity. In vivo, Liproxstatin-1 HCl reduces ferroptosis-mediated tissue injury, extending survival in acute renal failure and hepatic ischemia/reperfusion injury models (Wen et al. 2023).

Evidence & Benchmarks

• Liproxstatin-1 HCl inhibits ferroptosis in cell-based assays with an IC₅₀ of 22 nM in GPX4-deficient cells (APExBIO).
• It rescues primary human renal proximal tubule epithelial cells (HRPTEpiCs) from ferroptosis induced by RSL3, L-buthionine sulphoximine, and erastin, but not from staurosporine or H₂O₂-induced apoptosis/oxidative stress (APExBIO).
• In animal models, Liproxstatin-1 HCl reduces ferroptotic injury severity, decreases TUNEL-positive tubular cell death, and prolongs survival in acute renal failure (Wen et al. 2023).
• It is effective in protecting against hepatic ischemia/reperfusion injury in vivo, confirming broad tissue applicability (Wen et al. 2023).
• The compound is water-soluble (≥18.85 mg/mL) and DMSO-soluble (≥47.6 mg/mL), but insoluble in ethanol, facilitating flexible assay design (APExBIO).

This article extends the mechanistic and workflow detail provided in this summary by focusing on assay integration and selectivity boundaries. For advanced workflow troubleshooting and experimental tips, see our complementary guide. For broader context on translational application in hepatic injury, compare with this in-depth analysis.

Applications, Limits & Misconceptions

Liproxstatin-1 HCl is optimized for research on ferroptosis in acute renal failure, hepatic ischemia/reperfusion injury, and mechanistic studies of iron-dependent regulated cell death. It is used in cellular models (e.g., GPX4-deficient lines, HRPTEpiCs) and in vivo systems for quantifying ferroptosis, testing rescue strategies, and dissecting molecular pathways.

Common Pitfalls or Misconceptions

• Liproxstatin-1 HCl does not prevent cell death from apoptosis inducers (e.g., staurosporine) or from direct oxidative stress (e.g., H₂O₂).
• It is not a general antioxidant; it specifically targets lipid peroxidation in the context of ferroptosis.
• The compound is not suitable for diagnostic or clinical use; it is for research purposes only (APExBIO).
• It cannot reverse ferroptosis if lipid peroxidation damage is already irreversible or if GPX4 function is permanently lost.
• Use in ethanol-based systems is not recommended due to insolubility.

Workflow Integration & Parameters

Liproxstatin-1 HCl is supplied as a solid hydrochloride salt by APExBIO and should be stored at -20°C. Stock solutions can be prepared in DMSO (≥47.6 mg/mL) or water (≥18.85 mg/mL). For higher concentrations, warm and sonicate the solution. Working solutions should be freshly prepared or aliquoted and stored at -20°C for several months. The compound is compatible with standard cell culture and animal models. For ferroptosis assays, it is typically used at nanomolar concentrations (e.g., 22 nM for IC₅₀ in cell assays). It is compatible with standard inducers (RSL3, erastin, L-buthionine sulphoximine) and readouts (cell viability, lipid peroxidation, TUNEL assay).

Conclusion & Outlook

Liproxstatin-1 HCl is a gold-standard research tool for dissecting ferroptosis and lipid peroxidation. Its selectivity and nanomolar potency enable precise mechanistic studies and translational research in acute organ injury models. Future research will further define its therapeutic potential and mechanistic nuance in iron-dependent regulated cell death. For ordering or product specifications, see the Liproxstatin-1 HCl product page.